University of Calgary-born Parvus Therapeutics has inked an $800m deal with Genentech to develop and commercialise treatments for autoimmune diseases.
Parvus Therapeutics, a Canada-based biopharmaceutical spinout of University of Calgary, has signed a collaboration and licensing deal with biotechnology developer Genentech worth more than $800m.
The two companies will work together on the development, manufacturing and commercialisation of treatments based on Parvus’ Navacim platform. They will focus on inflammatory bowel disease, autoimmune liver diseases and coeliac disease.
Parvus will receive an upfront payment, and is eligible to receive research, development and commercialisation milestone payments. It is also eligible…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
